Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521887 | 0.83 | CYP11B1 (0.47) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| SCHEMBL4521885 | 0.80 | CYP11B1 (0.52) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| SCHEMBL4521891 | 0.76 | CYP11B2 (0.48) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| SCHEMBL4527947 | 0.76 | CYP11B1 (0.78) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| SCHEMBL10259875 | 0.73 | HTR2A (0.58) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| Hydrochloric Acid SCHEMBL4531569 | 0.72 | HTR2A (0.57) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| SCHEMBL4533237 | 0.72 | CYP11B1 (0.48) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| SCHEMBL4521679 | 0.72 | CYP11B1 (0.48) | CYP11B2CYP11B1HTR2AHTR2CEIF2AK3 | |
| SCHEMBL4525619 | 0.72 | ROCK2 (0.44) | — | |
| SCHEMBL4533562 | 0.71 | CYP11B2 (0.72) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | CYP11B2 911/4885CYP11B1 971/4885HTR2A 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.